These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 19699548)
1. Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer. Igawa S; Watanabe R; Ito I; Murakami H; Takahashi T; Nakamura Y; Tsuya A; Kaira K; Naito T; Endo M; Yamamoto N; Kameya T Lung Cancer; 2010 Jun; 68(3):438-45. PubMed ID: 19699548 [TBL] [Abstract][Full Text] [Related]
2. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study. Niho S; Kenmotsu H; Sekine I; Ishii G; Ishikawa Y; Noguchi M; Oshita F; Watanabe S; Nakajima R; Tada H; Nagai K J Thorac Oncol; 2013 Jul; 8(7):980-4. PubMed ID: 23774385 [TBL] [Abstract][Full Text] [Related]
3. Clinical features of unresectable high-grade lung neuroendocrine carcinoma diagnosed using biopsy specimens. Shimada Y; Niho S; Ishii G; Hishida T; Yoshida J; Nishimura M; Yoh K; Goto K; Ohmatsu H; Ohe Y; Nagai K Lung Cancer; 2012 Mar; 75(3):368-73. PubMed ID: 21920624 [TBL] [Abstract][Full Text] [Related]
4. Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer? Sun JM; Ahn MJ; Ahn JS; Um SW; Kim H; Kim HK; Choi YS; Han J; Kim J; Kwon OJ; Shim YM; Park K Lung Cancer; 2012 Aug; 77(2):365-70. PubMed ID: 22579297 [TBL] [Abstract][Full Text] [Related]
5. A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer). Kenmotsu H; Niho S; Ito T; Ishikawa Y; Noguchi M; Tada H; Sekine I; Watanabe S; Yoshimura M; Yamamoto N; Oshita F; Kubota K; Nagai K Lung Cancer; 2014 Jun; 84(3):254-8. PubMed ID: 24679951 [TBL] [Abstract][Full Text] [Related]
6. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC). Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059 [TBL] [Abstract][Full Text] [Related]
7. Weekly vinorelbine and docetaxel as second-line chemotherapy for pretreated non-small cell lung cancer patients: a phase I-II trial. Nelli F; Naso G; De Pasquale Ceratti A; Saltarelli R; Dauria G; Lugini A; Ferraldeschi R; Picone V; Moscetti L; Cortesi E J Chemother; 2004 Aug; 16(4):392-9. PubMed ID: 15332716 [TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection. Kang CH; Jang BG; Kim DW; Chung DH; Kim YT; Jheon S; Sung SW; Kim JH Lung Cancer; 2010 Jun; 68(3):478-83. PubMed ID: 19683826 [TBL] [Abstract][Full Text] [Related]
9. Irinotecan and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. A phase II study of the Hellenic Cooperative Oncology Group. Pectasides D; Fountzilas G; Rigopoulos A; Bountouroglou NG; Koutras A; Glotsos J; Onyenadum A; Makatsoris T; Kalofonos HP Anticancer Res; 2002; 22(6B):3501-6. PubMed ID: 12552946 [TBL] [Abstract][Full Text] [Related]
10. Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter? Derks JL; van Suylen RJ; Thunnissen E; den Bakker MA; Groen HJ; Smit EF; Damhuis RA; van den Broek EC; Speel EM; Dingemans AC; Eur Respir J; 2017 Jun; 49(6):. PubMed ID: 28572122 [TBL] [Abstract][Full Text] [Related]
11. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. Kim ES; Neubauer M; Cohn A; Schwartzberg L; Garbo L; Caton J; Robert F; Reynolds C; Katz T; Chittoor S; Simms L; Saxman S Lancet Oncol; 2013 Dec; 14(13):1326-36. PubMed ID: 24231627 [TBL] [Abstract][Full Text] [Related]
12. Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study. Zhang JT; Li Y; Yan LX; Zhu ZF; Dong XR; Chu Q; Wu L; Zhang HM; Xu CW; Lin G; Yu ZY; Hu J; Zhu B; Wang HJ; Yang F; Song ZB; Han ZB; Li MX; Lin J; Wu YL; Wang JL; Zhong WZ Lung Cancer; 2020 Jan; 139():118-123. PubMed ID: 31775086 [TBL] [Abstract][Full Text] [Related]
13. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival. Skov BG; Holm B; Erreboe A; Skov T; Mellemgaard A J Thorac Oncol; 2010 Apr; 5(4):453-9. PubMed ID: 20104194 [TBL] [Abstract][Full Text] [Related]
14. First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale. Gebbia V; Lorusso V; Galetta D; Caruso M M; Palomba G; Riccardi F; Borsellino N; Carrozza F; Leo S; FerraĆ¹ F; Cinieri S; Mancuso G; Mancarella S; Colucci G Lung Cancer; 2010 Aug; 69(2):218-24. PubMed ID: 19910076 [TBL] [Abstract][Full Text] [Related]
15. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Belani CP; Fossella F Cancer; 2005 Dec; 104(12):2766-74. PubMed ID: 16288485 [TBL] [Abstract][Full Text] [Related]
16. Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung. Fujiwara Y; Sekine I; Tsuta K; Ohe Y; Kunitoh H; Yamamoto N; Nokihara H; Yamada K; Tamura T Jpn J Clin Oncol; 2007 Jul; 37(7):482-6. PubMed ID: 17652109 [TBL] [Abstract][Full Text] [Related]
17. Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the Southwest Oncology Group (S0027). Hesketh PJ; Chansky K; Lau DH; Doroshow JH; Moinpour CM; Chapman RA; Goodwin JW; Gross HM; Crowley JJ; Gandara DR J Thorac Oncol; 2006 Jul; 1(6):537-44. PubMed ID: 17409914 [TBL] [Abstract][Full Text] [Related]
18. Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer. Sekine I; Nokihara H; Sumi M; Saijo N; Nishiwaki Y; Ishikura S; Mori K; Tsukiyama I; Tamura T J Thorac Oncol; 2006 Oct; 1(8):810-5. PubMed ID: 17409964 [TBL] [Abstract][Full Text] [Related]
19. Discriminant model for cytologic distinction of large cell neuroendocrine carcinoma from small cell carcinoma of the lung. Hoshi R; Furuta N; Horai T; Ishikawa Y; Miyata S; Satoh Y J Thorac Oncol; 2010 Apr; 5(4):472-8. PubMed ID: 20125039 [TBL] [Abstract][Full Text] [Related]
20. A clinicopathological study of peripheral, small-sized high-grade neuroendocrine tumours of the lung: differences between small-cell lung carcinoma and large-cell neuroendocrine carcinoma. Isaka M; Nakagawa K; Ohde Y; Okumura T; Watanabe R; Ito I; Nakajima T; Kondo H Eur J Cardiothorac Surg; 2012 Apr; 41(4):841-6. PubMed ID: 22219429 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]